Published online Dec 24, 2021. doi: 10.5306/wjco.v12.i12.1193
Peer-review started: June 23, 2021
First decision: July 27, 2021
Revised: June 27, 2021
Accepted: November 26, 2021
Article in press: November 26, 2021
Published online: December 24, 2021
Processing time: 183 Days and 18.9 Hours
The liver is the most common site of colorectal cancer metastasis. Complete resection of the metastatic tumor is currently the only treatment modality available with a potential for cure. However, only 20% of colorectal liver metastases (CRLM) are considered resectable at the time of presentation. Liver transplantation (LT) has been proposed as an alternative oncologic treatment for patients with unresectable CRLM. This review summarizes the published experiences of LT in the setting of unresectable CRLM from the previous decades and discusses the challenges and future horizons in the field. Contemporary experiences that come mostly from countries with broader access to liver grafts are also explored and their promising findings in terms of overall survival (OS) and disease-free survival (DFS) are outlined along with their study design and methods. The rationale of establishing specific patient selection criteria and the dilemmas around immunosuppressive regimens in patients undergoing LT for CRLM are also highlighted. Additionally, this review describes the findings of studies comparing LT vs chemotherapy alone and LT vs portal vein embolization plus resection for CRLM in terms of OS and DFS. Last but not least, we present current perspectives and ongoing prospective trials that try to elucidate the role of LT for CRLM.
Core Tip: Despite the discouraging results of the previous decades, reports from the recent era showed promising results and reemerged the idea of liver transplantation (LT) for colorectal liver metastases (CRLM). Documentation of patient selection criteria and stronger evidence from ongoing prospective trials may reinforce the implementation of LT as an oncologic treatment for CRLM.